What we are studying
The purpose of the study is to see if a medicine called ASP2215 is both effective and safe as a treatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3 Mutation Assay companion diagnostic (a specific way to test your blood or bone marrow, which is used to see have a mutation of the FLT3 gene), compared to salvage chemotherapy. Some AML patients have a mutation in the gene called FLT3. When patients have a FLT3 mutation, more of the FLT3 protein is on the leukemic cells, or the protein is more active. This may make the leukemic cells grow faster or live longer.
Parking will be validated for all study related visits.